65 66

Cited 0 times in

Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study.

DC FieldValueLanguage
dc.contributor.author이승환-
dc.date.accessioned2018-07-20T07:48:23Z-
dc.date.available2018-07-20T07:48:23Z-
dc.date.issued2017-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/160541-
dc.description.abstractPURPOSE: To investigate the efficacy and safety of naftopidil for benign prostatic hyperplasia (BPH) patients, mainly focusing on changes in blood pressure (BP). MATERIALS AND METHODS: Of a total of 118 patients, 90 normotensive (NT) and 28 hypertensive (HT) patients were randomly assigned to be treated with naftopidil 50 mg or 75 mg for 12 weeks, once-daily. Safety and efficacy were assessed by analyzing changes from baseline in systolic/diastolic BP and total International Prostate Symptom Score (IPSS) at 4 and 12 weeks. Adverse events (AEs), obstructive/irritative subscores, quality of life (QoL) score, maximum urinary flow rate (Qmax), and benefit, satisfaction with treatment, and willingness to continue treatment (BSW) questionnaire were also analyzed. RESULTS: Naftopidil treatment decreased mean systolic BP by 18.7 mm Hg for the HT 50 mg group (p<0.001) and by 18.3 mm Hg for the HT 75 mg group (p<0.001) and mean diastolic BP by 17.5 mm Hg for the HT 50 mg group (p<0.001) and by 14.7 mm Hg for the HT 75 mg group (p=0.022). In the NT groups (both naftopidil 50 mg and 75 mg), naftopidil elicited no significant changes in BP from baseline values. After 12 weeks, naftopidil 50 and 75 mg groups showed significant improvements in IPSS scores (total, obstructive/irritative subscores, QoL score) and Qmax from baseline. AEs were reported in 7.8% (50 mg group) and 2.9% (75 mg group) of patients. In both the 50 mg and 75 mg groups, >86% of all patients agreed to continue their current medications. CONCLUSION: Our results suggest that naftopidil treatment in BPH patients with hypertension allows for optimal management of BP within the normal range.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherYonsei University-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdrenergic alpha-Antagonists/adverse effects-
dc.subject.MESHAdrenergic alpha-Antagonists/pharmacology-
dc.subject.MESHAdrenergic alpha-Antagonists/therapeutic use-
dc.subject.MESHAged-
dc.subject.MESHBlood Pressure/drug effects-
dc.subject.MESHDemography-
dc.subject.MESHHumans-
dc.subject.MESHHypertension/complications*-
dc.subject.MESHHypertension/drug therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNaphthalenes/adverse effects*-
dc.subject.MESHNaphthalenes/pharmacology-
dc.subject.MESHNaphthalenes/therapeutic use*-
dc.subject.MESHPatient Compliance-
dc.subject.MESHPatient Satisfaction-
dc.subject.MESHPiperazines/adverse effects*-
dc.subject.MESHPiperazines/pharmacology-
dc.subject.MESHPiperazines/therapeutic use*-
dc.subject.MESHProspective Studies-
dc.subject.MESHProstatic Hyperplasia/complications*-
dc.subject.MESHProstatic Hyperplasia/drug therapy*-
dc.subject.MESHQuality of Life-
dc.subject.MESHSurveys and Questionnaires-
dc.subject.MESHTreatment Outcome-
dc.titleClinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Urology-
dc.contributor.googleauthorMun Su Chung-
dc.contributor.googleauthorByung Il Yoon-
dc.contributor.googleauthorSeung Hwan Lee-
dc.identifier.doi10.3349/ymj.2017.58.4.800-
dc.contributor.localIdA02938-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid28540994-
dc.subject.keywordBPH-
dc.subject.keywordhypertension-
dc.subject.keywordnaftopidil-
dc.subject.keywordα-adrenoceptor antagonists-
dc.contributor.alternativeNameLee, Seung Hwan-
dc.contributor.affiliatedAuthorLee, Seung Hwan-
dc.citation.volume58-
dc.citation.number4-
dc.citation.startPage800-
dc.citation.endPage806-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.58(4) : 800-806, 2017-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.